<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01420341</url>
  </required_header>
  <id_info>
    <org_study_id>HE541074</org_study_id>
    <secondary_id>project number 542040</secondary_id>
    <secondary_id>106698/B/14/Z</secondary_id>
    <nct_id>NCT01420341</nct_id>
  </id_info>
  <brief_title>Co-trimoxazole as Maintenance Therapy for Melioidosis</brief_title>
  <official_title>A Comparison Between 12 vs. 20 Weeks of Co-trimoxazole as Maintenance Therapy for Melioidosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Khon Kaen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Khon Kaen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomised, open-labelled, controlled trial to compare the efficacy and&#xD;
      effectiveness on relapse-free rate of 12-week versus 20-week oral eradication treatment of&#xD;
      melioidosis. The study population includes 800 patients with culture-confirmed melioidosis&#xD;
      whom 12 weeks of oral eradication therapy have been completed with or without intravenous&#xD;
      intensive antibiotics. Patients will be randomised to either stop the eradication treatment&#xD;
      or continue current oral treatment for 8 more weeks. The study aim to optimise the regimen&#xD;
      used to treat melioidosis for better compliance and reducing unnecessary use of antibiotics.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Planed interim analysis will be conducted when the patient enrollment reaches 600 cases for&#xD;
      evaluating safety and futility of the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">June 21, 2019</completion_date>
  <primary_completion_date type="Actual">June 21, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1-year non relapse rate</measure>
    <time_frame>1 year</time_frame>
    <description>This is defined as clinical features of melioidosis after initial improvement, in association with cultures from any site positive for Burkhoderia pseudomallei. This can be any time point during or after stopping antibiotic treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Recurrence</measure>
    <time_frame>1 year</time_frame>
    <description>Recurrent clinical features of melioidosis treated as such but not confirmed by positive culture.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment failure</measure>
    <time_frame>9 weeks</time_frame>
    <description>Clinical decision to change treatment according to inadequate response to therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Drug Reactions</measure>
    <time_frame>9 weeks</time_frame>
    <description>Adverse events that are caused by the drug including drug allergy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug compliance</measure>
    <time_frame>12 or 20 weeks</time_frame>
    <description>This will be done by interviewing and pill counting.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">667</enrollment>
  <condition>Melioidosis</condition>
  <arm_group>
    <arm_group_label>Co-trimoxazole 12</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Receive treatment with co-trimoxazole for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Co-trimoxazole 20</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Receive treatment with co-trimoxazole for 20 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Co-trimoxazole 12</intervention_name>
    <description>Receive treatment with co-trimoxazole for 12 weeks.</description>
    <arm_group_label>Co-trimoxazole 12</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Co-trimoxazole 20</intervention_name>
    <description>Receive treatment with co-trimoxazole for 20 weeks.</description>
    <arm_group_label>Co-trimoxazole 20</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age &gt; 15 years&#xD;
&#xD;
          2. Culture-confirmed melioidosis&#xD;
&#xD;
          3. Currently on oral co-trimoxazole for 12(+2) weeks without any clinical evidence of&#xD;
             active melioidosis&#xD;
&#xD;
          4. High likelihood of completing at least 6 months follow up&#xD;
&#xD;
          5. Willingness to participate in the study and written, informed consent obtained from&#xD;
             the patient&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnancy or breast feeding&#xD;
&#xD;
          2. Contraindications to TMP-SMX: G6PD, severe adverse reactions grade 3-4 occurring&#xD;
             during first 12 weeks of treatment&#xD;
&#xD;
          3. Relapse melioidosis with at least 2 year symptom free period from last episode&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Siriluck Anunnatsiri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Khon Kaen Univerisity</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Khon Kaen Univerisity</name>
      <address>
        <city>Khon Kaen</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>August 18, 2011</study_first_submitted>
  <study_first_submitted_qc>August 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2011</study_first_posted>
  <last_update_submitted>September 1, 2020</last_update_submitted>
  <last_update_submitted_qc>September 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Khon Kaen University</investigator_affiliation>
    <investigator_full_name>Siriluck Anunnatsiri</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Melioidosis</keyword>
  <keyword>Co-trimoxazole</keyword>
  <keyword>Relapse</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melioidosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trimethoprim, Sulfamethoxazole Drug Combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

